Harvard Bioscience, Inc. (HBIO) Reaches $5.00 After 8.00% Up Move; Cannell Capital Boosted By $560,000 Its Weyerhaeuser Co (WY) Position

April 8, 2018 - By Peter Kolinski

Weyerhaeuser Company (NYSE:WY) Logo

Cannell Capital Llc increased Weyerhaeuser Co (WY) stake by 78.49% reported in 2017Q4 SEC filing. Cannell Capital Llc acquired 16,000 shares as Weyerhaeuser Co (WY)’s stock declined 0.11%. The Cannell Capital Llc holds 36,386 shares with $1.28 million value, up from 20,386 last quarter. Weyerhaeuser Co now has $26.83 billion valuation. The stock decreased 0.73% or $0.26 during the last trading session, reaching $35.48. About 3.79 million shares traded. Weyerhaeuser Company (NYSE:WY) has risen 4.15% since April 8, 2017 and is uptrending. It has underperformed by 7.40% the S&P500.

The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) is a huge mover today! The stock increased 2.04% or $0.1 during the last trading session, reaching $5. About 125,052 shares traded. Harvard Bioscience, Inc. (NASDAQ:HBIO) has risen 87.27% since April 8, 2017 and is uptrending. It has outperformed by 75.72% the S&P500.The move comes after 8 months positive chart setup for the $177.97M company. It was reported on Apr, 8 by Barchart.com. We have $5.40 PT which if reached, will make NASDAQ:HBIO worth $14.24 million more.

Among 14 analysts covering Weyerhaeuser Company (NYSE:WY), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Weyerhaeuser Company had 35 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Weyerhaeuser Company (NYSE:WY) earned “Strong Buy” rating by Raymond James on Monday, January 9. As per Wednesday, June 29, the company rating was upgraded by DA Davidson. BMO Capital Markets downgraded the stock to “Market Perform” rating in Monday, August 14 report. The firm has “Buy” rating by Argus Research given on Tuesday, March 15. RBC Capital Markets maintained it with “Buy” rating and $40.0 target in Wednesday, November 8 report. On Thursday, November 2 the stock rating was maintained by Argus Research with “Buy”. The stock of Weyerhaeuser Company (NYSE:WY) earned “Buy” rating by Bank of America on Wednesday, January 24. The firm earned “Neutral” rating on Friday, August 12 by Dundee Securities. The firm has “Buy” rating given on Tuesday, January 19 by Dundee Securities. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, November 17.

Since October 16, 2017, it had 0 insider purchases, and 1 insider sale for $7.97 million activity. $7.97M worth of Weyerhaeuser Company (NYSE:WY) was sold by HOLLEY RICK R on Monday, October 16.

Investors sentiment increased to 1.14 in Q4 2017. Its up 0.04, from 1.1 in 2017Q3. It is positive, as 34 investors sold WY shares while 268 reduced holdings. 71 funds opened positions while 272 raised stakes. 545.30 million shares or 1.12% less from 551.50 million shares in 2017Q3 were reported. Frontier Mngmt reported 12,635 shares. Telemus Ltd Liability Co holds 0.4% or 145,337 shares. Sg Americas Securities Ltd Co owns 169,649 shares or 0.06% of their US portfolio. Clifford Swan Investment Counsel Ltd Liability Corp accumulated 133,906 shares or 0.26% of the stock. Hl Fincl Serv Limited Liability Com holds 0.03% of its portfolio in Weyerhaeuser Company (NYSE:WY) for 38,860 shares. Renaissance Technology owns 122,981 shares. Pitcairn Company accumulated 0.04% or 11,062 shares. Pennsylvania Trust holds 174,889 shares. Folger Nolan Fleming Douglas Mgmt holds 0.08% or 16,004 shares in its portfolio. Oarsman Capital owns 6,826 shares or 0.1% of their US portfolio. West Coast Fincl Ltd Company has 0.17% invested in Weyerhaeuser Company (NYSE:WY). Pekin Singer Strauss Asset Il invested 0.26% in Weyerhaeuser Company (NYSE:WY). Syntal Prtnrs Limited Company, a Texas-based fund reported 9,209 shares. Chesley Taft And Assoc Limited Liability Company owns 170,382 shares. Columbia Partners L L C Management reported 56,029 shares.

Since March 7, 2018, it had 0 insider buys, and 3 insider sales for $1.00 million activity. $393,963 worth of Harvard Bioscience, Inc. (NASDAQ:HBIO) shares were sold by Duchemin Jeffrey. Shares for $448,542 were sold by Gagnon Robert E. on Wednesday, March 7. The insider UVEGES GEORGE sold 35,054 shares worth $161,599.

Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on April, 26. HBIO’s profit will be $355,948 for 125.00 P/E if the $0.01 EPS becomes a reality. After $0.04 actual EPS reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts -75.00% negative EPS growth.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $177.97 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Weyerhaeuser Company (NYSE:WY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>